In minimally classic/occult trial of the anti-VEGF antibody ranibizumab in the treatment of neovascular age-related macular degeneration (MARINA) study, patients receiving the 0.5 mg dose of ranibizumab experienced a 21.4 letter improvement compared with sham injections, and in ANCHOR, they demonstrated a 20.5 letter improvement compared with those receiving photodynamic therapy [22]. This evidence concerns the gene VEGFA and wet macular degeneration.